MENLO PARK, Calif., November 16, 2009
- Geron Corporation (Nasdaq: GERN) today announced that Thomas B. Okarma, Ph.D., M.D., president and chief executive officer, will present an update of the company's product development programs at 11:30 a.m. ET on Wednesday, November 18, 2009, at the Lazard Capital Markets 6th Annual Healthcare Conference in New York City.
The update will include information about Geron's portfolio of anti-cancer therapies, including its telomerase inhibitor drug (imetelstat sodium - GRN163L) and its telomerase therapeutic vaccine (GRNVAC1). The presentation will also include a review of the company's human embryonic stem cell development programs for spinal cord injury (GRNOPC1), heart disease (GRNCM1), diabetes (GRNIC1), and osteoarthritis (GRNCHND1).
The audio and slide presentation will be available at the following web site address: http://www.wsw.com/webcast/lz6/gern/. The presentation will be archived for replay at the same address within 24 hours of the live presentation for a period of 30 days.
About Geron
Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials in different cancers. For more information about Geron, visit www.geron.com.
CONTACT:
Anna Krassowska, Ph.D.
Investor and Media Relations
650-473-7765 info@geron.com
